Blog

The FDA agrees that the Company may follow 505(b)(2) regulatory pathway to non-invasively treat basal cell carcinoma (BCC) of the skin using dissolvable Doxorubicin-containing Microneedle arrays (D-MNA) representing ~$2 billion in potential market opportunity

The Company plans to complete patient recruitment for SKNJCT-003 before the end of Q4 2025 and to request End-of-Phase 2 (EOP2) with the FDA in Q1 2026

PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / September 29, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce positive feedback from Type C meeting with United States Food and Drug Administration (FDA).

The purpose of the Type C meeting was to discuss the design, endpoints, and other key protocol elements for the clinical development of doxorubicin containing microneedle array (D-MNA) to non-invasively treat basal cell carcinoma (BCC) of the skin.

The FDA provided clarity and further alignment that a relative bioavailability study with the Company’s D-MNA product to treat BCC administered under certain conditions could provide support towards establishing a clinical bridge for the 505(b)(2) regulatory pathway as well as help satisfy the bioavailability requirement of the Company’s D-MNA product as stated in 21CFR320.21. More specifically, the FDA provided positive and constructive feedback on a number of topics for the continued development of Skinject including, but not limited to: the appropriate primary endpoint for the next study; proposed patient population definition, including tumor size limits, location restrictions, and histological confirmation requirements; proposed randomized, double-blind, placebo-controlled, study design for future studies that are intended to demonstrate the effectiveness of D-MNA in treating BCC; and current safety assessments for the proposed study.

In anticipation of future pivotal studies, the FDA also provided recommendations to continue to optimize formulation and microneedle design, integrate an adhesive layer to affix the microneedle system to the body, and incorporate the use of an applicator to consistently apply the product to the application site.

“Establishing 505(b)(2) as a regulatory pathway to bring to market our novel, non-invasive Skinject D-MNA treatment to cure BCC of the skin, is a game changer” stated Dr. Raza Bokhari, Medicus’s Executive Chairman & CEO, “by leveraging existing doxorubicin safety data, we will not only realize substantial drug development cost savings but also time savings compared to a traditional full development program. As we plan to complete patient recruitment for SKNJCT-003 before the end this year and request an EOP2 meeting with the FDA in Q1 2026, our confidence is increasing that Skinject may become commercially viable sometime in 2027”.

The Company is currently conducting a Phase 2 clinical study for SKNJCT-003 in nine (9) clinical sites across the United States which commenced randomizing patients in August 2024. In March 2025, the Company also announced a positively trending interim analysis for SKNJCT-003 demonstrating more than 60% clinical clearance. The interim analysis was conducted after more than 50% of the then-targeted 60 patients in the study were randomized. The findings of the interim analysis are preliminary and may or may not correlate with the findings of the study once completed. In April 2025, the investigational review board approved to increase the number of participants in SKNJCT-003 to ninety (90) subjects. The Company is expanding its trial sites in Europe and has randomized more than 75% of the ninety (90) participants expected to be randomized in the study.

The Company also has a clinical study (SKNJCT-004) currently underway in the United Arab Emirates (UAE). The study is expected to randomize thirty-six (36) patients in six (6) sites in the UAE. Cleveland Clinic Abu Dhabi (CCAD) is the principal investigator, along with Sheikh Shakbout Medical City (SSMC), Burjeel Medical City (BMC), Rashid Hospital (RH), Clemenceau Medical Center (CMC) and American Hospital of Dubai (AHD). Insights Research Organization and Solutions (IROS), a UAE-based contract research organization, is coordinating the clinical study for the Company. IROS is a M42 portfolio company.

In August 2025, the Company completed the acquisition of Antev, a UK-based late clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse (AURr) episodes due to enlarged prostate.

Antev’s flagship drug candidate is Teverelix trifluoroacetate (Teverelix TFA), a long-acting gonadotrophin-releasing hormone (GnRH) antagonist. Unlike GnRH agonists, which can cause an initial surge in testosterone levels, Teverelix directly suppresses sex hormone production without this surge, potentially reducing cardiovascular risks. This mechanism is particularly beneficial for patients with existing cardiovascular conditions. Teverelix is formulated as a microcrystalline suspension, allowing for sustained release and a six-week dosing interval, which may improve patient compliance and outcomes.

For further information contact:

Carolyn Bonner, President and Acting Chief Financial Officer
(610) 636-0184
cbonner@medicuspharma.com

Anna Baran-Djokovic, SVP Investor Relations
(305) 615-9162
adjokovic@medicspharma.com

About Medicus Pharma Ltd.

Medicus Pharma Ltd. (Nasdaq:MDCX) is a biotech/life sciences company focused on accelerating the clinical development programs of novel and potentially disruptive therapeutics assets. The Company is actively engaged in multiple countries, spread over three continents.

SkinJect Inc. a wholly owned subsidiary of Medicus Pharma Ltd., is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver a chemotherapeutic agent to eradicate tumors cells. The Company completed a phase 1 safety & tolerability study (SKNJCT-001) in March of 2021, which met its primary objective of safety and tolerability; the study also describes the efficacy of the investigational product D-MNA, with six (6) participants experiencing complete response on histological examination of the resected lesion. The Company is currently conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in the United States and Europe. The Company has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in the United Arab Emirates.

In August 2025, the Company announced its entry into a non-binding memorandum of understanding (the “MoU”) with Helix Nanotechnologies, Inc. (“HelixNano”), a Boston Based biotech company focused on developing a proprietary advanced mRNA platform, in respect of their shared mutual interest in the development or commercial arrangement contemplated by the MoU. The MoU is non-binding and shall not be construed to obligate either party to proceed with a joint venture or any further development or commercial arrangement, unless and until definitive agreements are executed.

In August 2025, the Company completed the acquisition of Antev, a UK-based late clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse (AURr) episodes due to enlarged prostate.

Antev’s flagship drug candidate is Teverelix trifluoroacetate (Teverelix TFA), a long-acting gonadotrophin-releasing hormone (GnRH) antagonist. Unlike GnRH agonists, which can cause an initial surge in testosterone levels, Teverelix directly suppresses sex hormone production without this surge, potentially reducing cardiovascular risks. This mechanism is particularly beneficial for patients with existing cardiovascular conditions. Teverelix is formulated as a microcrystalline suspension, allowing for sustained release and a six-week dosing interval, which may improve patient compliance and outcomes.

In September 2020, Antev completed a Phase 1 clinical trial in which Teverelix was shown to be well tolerated with no dose-limiting toxicities and demonstrated rapid testosterone suppression. The study included 48 healthy male volunteers. In February 2023, Antev also completed a Phase 2a study in fifty (50) patients with advanced prostate cancer (APC), where Teverelix achieved the primary endpoint of greater than 90% probability of castration levels of testosterone suppression (97.5%) but the secondary endpoint of maintaining this rate above 90% was not met with the probability dropping to 82.5% by Day 42.

In January 2023, the FDA, reviewed the Phase 1 and Phase 2a data and provided written guidance on Antev’s proposed Phase 3 trial design for Teverelix. This milestone supports the Company’s clinical plans to develop Teverelix as a treatment for advanced prostate cancer patients with increased cardiovascular risk.

In December 2023, FDA approved the Phase 2b study design in advanced prostate cancer covering 40 patients.

In November 2024, FDA approved the Phase 2b study design in acute urinary retention covering 390 patients.

Cautionary Notice on Forward-Looking Statements

Certain information in this news release constitutes “forward-looking information” under applicable securities laws. “Forward-looking information” is defined as disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action and includes, without limitation, the development of Teverelix and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of Teverelix for AURr and high CV risk prostate cancer, and the potential market opportunities related thereto, the MOU, including the potential signing of definitive agreements between Medicus and HelixNano and the development of thermostable infectious diseases vaccines by combining HelixNano’s proprietary mRNA vaccine platform with Medicus’s proprietary microneedle array (MNA) delivery platform, the Company’s aim to fast-track the clinical development program and convert the SKNJCT-003 exploratory clinical trial into a pivotal clinical trial, and approval from the FDA and the timing thereof, plans and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of SkinJect through SKNJCT-003 and SKNJCT-004, and the potential market opportunities related thereto, the commencement of the SKNJCT-004 study and the potential results of and benefits of such study. Forward-looking statements are often but not always, identified by the use of such terms as “may”, “on track”, “aim”, “might”, “will”, “will likely result”, “could,” “designed,” “would”, “should”, “estimate”, “plan”, “project”, “forecast”, “intend”, “expect”, “anticipate”, “believe”, “seek”, “continue”, “target”, “potential” or the negative and/or inverse of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including those risk factors described in the Company’s annual report on form 10-K for the year ended December 31, 2024 (the “Annual Report”), and in the Company’s other public filings on EDGAR and SEDAR+, which may impact, among other things, the trading price and liquidity of the Company’s common shares. . Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

SOURCE: Medicus Pharma Ltd

View the original press release on ACCESS Newswire

Targeting Phase 1 commissioning by the end of 2026

HIGHLIGHTS

• Existing fully permitted Central Gawler Mill adjacent to brownfield Challenger mines

• Challenger JORC (2012) Mineral Resources Estimate now 313koz Au (10.6Mt @ 0.92 g/t), including 194koz Au (1.87Mt @ 3.23 g/t) in existing open pit and underground mines, where:

  • Challenger Main Open Pit: 70,000oz Au (0.65Mt @ 3.36 g/t Au);

  • Challenger West Open pit: 11,600oz Au (0.03Mt @ 10.7 g/t Au);

  • Challenger Underground (above 215mRL): 89,400oz Au (0.98Mt @ 2.84 g/t Au); and

  • Challenger Deeps (below 90mRL): 23,000oz Au (0.21Mt @ 3.50 g/t Au).

• Historical tailings storage facility with coarse, higher-grade tailings up to 0.6 – 1.0 g/t Au

• Evaluating de-risked, two phase transition to operations with initial tailings reprocessing (‘Phase 1’) followed by the introduction of high-grade (~3 g/t) fresh ore (‘Phase 2’)

• Targeting Phase 1 commissioning by end of 2026; credit finance conversations underway

ADELAIDE, AU / ACCESS Newswire / September 28, 2025 / Barton Gold Holdings Limited (ASX:BGD)(OTCQB:BGDFF)(FRA:BGD3) (Barton or Company) is pleased to announced that a Definitive Feasibility Study (DFS) has started, targeting ‘Stage 1’ production utilising the fully permitted Central Gawler Mill (CGM) located at Barton’s South Australian Challenger Gold Project (Challenger).

The JORC (2012) Mineral Resource Estimate (MRE) for Challenger was recently upgraded to 313koz Au, including 194koz Au high-grade fresh ore (~3.2 g/t Au) in or adjacent to existing serviceable open pit and underground development, and an historical Tailings Storage Facility 1 (TSF1) containing 56koz Au at a grade of 0.54 g/t Au.²

Barton is targeting March 2026 DFS completion and end of 2026 CGM commissioning, with ‘Phase 1’ operations reprocessing TSF1 materials, and ‘Phase 2’ then introducing fresh ore. Altris Pty Ltd (Altris) has been appointed to lead the DFS, with SRK Consulting (Australasia) Pty Ltd (SRK Consulting) completing TSF1 mining studies, Tetra Tech Coffey Pty Ltd (Tetra Tech Coffey) designing a tailings storage lift, and GPA Engineering Pty Ltd (GPA) supporting engineering, metallurgy and process plant design. Technical site visits will begin this week.

Full details are contained in the complete announcement, which can be accessed on the ASX website, the investor section of Barton’s website, or directly by clicking here.

Commenting on the start of the Stage 1 DFS, Barton Managing Director Alexander Scanlon said:

“With gold prices at all-time highs and over 300koz Au JORC Resources adjacent to the Central Gawler Mill, the opportunity to leverage our existing infrastructure to operations and cash flow has never been more attractive.

“We are wasting no time pursuing this opportunity, targeting a low-cost and low-risk transition to operations by the end of 2026, the re-rating of Barton’s equity to a ‘producer’ profile, and operating free cash flows to fund our planned regional growth at Tunkillia. We look forward to sharing regular updates during an exciting 18 months ahead.”

Authorised by the Managing Director of Barton Gold Holdings Limited.

For further information, please contact:

Alexander Scanlon Managing Director a.scanlon@bartongold.com.au +61 425 226 649

Jade Cook Company Secretary cosec@bartongold.com.au +61 8 9322 1587

About Barton Gold
Barton Gold is an ASX, OTCQB and Frankfurt Stock Exchange listed Australian gold developer targeting future gold production of 150,000ozpa with 2.2Moz Au & 3.1Moz Ag JORC Mineral Resources (79.9Mt @ 0.87g/t Au), brownfield mines, and 100% ownership of the region’s only gold mill in the renowned Gawler Craton of South Australia.*

Challenger Gold Project 313koz Au + fully permitted Central Gawler Mill (CGM) Tarcoola Gold Project 20koz Au in fully permitted open pit mine near CGM Tolmer discovery grades up to 84g/t Au & 17,600g/t Ag Tunkillia Gold Project 1.6Moz Au & 3.1Moz Ag JORC Mineral Resources Competitive 120kozpa gold & 250kozpa silver project Wudinna Gold Project 279koz Au project located southeast of Tunkillia Significant optionality, adjacent to main highway

Competent Persons Statement & Previously Reported Information
The information in this announcement that relates to the historic Exploration Results and Mineral Resources as listed in the table below is based on, and fairly represents, information and supporting documentation prepared by the Competent Person whose name appears in the same row, who is an employee of or independent consultant to the Company and is a Member or Fellow of the Australasian Institute of Mining and Metallurgy (AusIMM), Australian Institute of Geoscientists (AIG) or a Recognised Professional Organisation (RPO). Each person named in the table below has sufficient experience which is relevant to the style of mineralisation and types of deposits under consideration and to the activity which he has undertaken to quality as a Competent Person as defined in the JORC Code 2012 (JORC).

Activity	Competent Person	Membership	Status
Tarcoola Mineral Resource (Stockpiles)	Dr Andrew Fowler (Consultant)	AusIMM	Member
Tarcoola Mineral Resource (Perseverance Mine)	Mr Ian Taylor (Consultant)	AusIMM	Fellow
Tarcoola Exploration Results (until 15 Nov 2021)	Mr Colin Skidmore (Consultant)	AIG	Member
Tarcoola Exploration Results (after 15 Nov 2021)	Mr Marc Twining (Employee)	AusIMM	Member
Tunkillia Exploration Results (until 15 Nov 2021)	Mr Colin Skidmore (Consultant)	AIG	Member
Tunkillia Exploration Results (after 15 Nov 2021)	Mr Marc Twining (Employee)	AusIMM	Member
Tunkillia Mineral Resource	Mr Ian Taylor (Consultant)	AusIMM	Fellow
Challenger Mineral Resource (above 215mRL)	Mr Ian Taylor (Consultant)	AusIMM	Fellow
Challenger Mineral Resource (below 90mRL)	Mr Dale Sims	AusIMM / AIG	Fellow / Member
Wudinna Mineral Resource (Clarke Deposit)	Ms Justine Tracey	AusIMM	Member
Wudinna Mineral Resource (all other Deposits)	Mrs Christine Standing	AusIMM / AIG	Member / Member

The information relating to historic Exploration Results and Mineral Resources in this announcement is extracted from the Company’s Prospectus dated 14 May 2021 or as otherwise noted in this announcement, available from the Company’s website at www.bartongold.com.au or on the ASX website www.asx.com.au. The Company confirms that it is not aware of any new information or data that materially affects the Exploration Results and Mineral Resource information included in previous announcements and, in the case of estimates of Mineral Resources, that all material assumptions and technical parameters underpinning the estimates, and any production targets and forecast financial information derived from the production targets, continue to apply and have not materially changed. The Company confirms that the form and context in which the applicable Competent Persons’ findings are presented have not been materially modified from the previous announcements.

Cautionary Statement Regarding Forward-Looking Information

This document may contain forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “expect”, “target” and “intend” and statements than an event or result “may”, “will”, “should”, “would”, “could”, or “might” occur or be achieved and other similar expressions. Forward-looking information is subject to business, legal and economic risks and uncertainties and other factors that could cause actual results to differ materially from those contained in forward-looking statements. Such factors include, among other things, risks relating to property interests, the global economic climate, commodity prices, sovereign and legal risks, and environmental risks. Forward-looking statements are based upon estimates and opinions at the date the statements are made. Barton undertakes no obligation to update these forward-looking statements for events or circumstances that occur subsequent to such dates or to update or keep current any of the information contained herein. Any estimates or projections as to events that may occur in the future (including projections of revenue, expense, net income and performance) are based upon the best judgment of Barton from information available as of the date of this document. There is no guarantee that any of these estimates or projections will be achieved. Actual results will vary from the projections and such variations may be material. Nothing contained herein is, or shall be relied upon as, a promise or representation as to the past or future. Any reliance placed by the reader on this document, or on any forward-looking statement contained in or referred to in this document will be solely at the readers own risk, and readers are cautioned not to place undue reliance on forward-looking statements due to the inherent uncertainty thereof.

SOURCE: Barton Gold Holdings Limited

View the original press release on ACCESS Newswire

ADELAIDE, AU / ACCESS Newswire / September 28, 2025 / Barton Gold Holdings Limited (ASX:BGD) (Barton or the Company) advises that the Annual Report for the year ended 30 June 2025 has been released to the market.

A copy of this Annual Report can be accessed on the ASX website, the investor section of Barton’s website, or directly by clicking here.

Authorised by the Managing Director of Barton Gold Holdings Limited.

For further information, please contact:

Alexander Scanlon Managing Director a.scanlon@bartongold.com.au +61 425 226 649

Jade Cook Company Secretary cosec@bartongold.com.au +61 8 9322 1587

About Barton Gold
Barton Gold is an ASX, OTCQB and Frankfurt Stock Exchange listed Australian gold developer targeting future gold production of 150,000ozpa with 2.2Moz Au & 3.1Moz Ag JORC Mineral Resources (79.9Mt @ 0.87g/t Au), brownfield mines, and 100% ownership of the region’s only gold mill in the renowned Gawler Craton of South Australia.*

Challenger Gold Project 313koz Au + fully permitted Central Gawler Mill (CGM) Tarcoola Gold Project 20koz Au in fully permitted open pit mine near CGM Tolmer discovery grades up to 84g/t Au & 17,600g/t Ag Tunkillia Gold Project 1.6Moz Au & 3.1Moz Ag JORC Mineral Resources Competitive 120kozpa gold & 250kozpa silver project Wudinna Gold Project 279koz Au project located southeast of Tunkillia Significant optionality, adjacent to main highway

Competent Persons Statement & Previously Reported Information
The information in this announcement that relates to the historic Exploration Results and Mineral Resources as listed in the table below is based on, and fairly represents, information and supporting documentation prepared by the Competent Person whose name appears in the same row, who is an employee of or independent consultant to the Company and is a Member or Fellow of the Australasian Institute of Mining and Metallurgy (AusIMM), Australian Institute of Geoscientists (AIG) or a Recognised Professional Organisation (RPO). Each person named in the table below has sufficient experience which is relevant to the style of mineralisation and types of deposits under consideration and to the activity which he has undertaken to quality as a Competent Person as defined in the JORC Code 2012 (JORC).

Activity	Competent Person	Membership	Status
Tarcoola Mineral Resource (Stockpiles)	Dr Andrew Fowler (Consultant)	AusIMM	Member
Tarcoola Mineral Resource (Perseverance Mine)	Mr Ian Taylor (Consultant)	AusIMM	Fellow
Tarcoola Exploration Results (until 15 Nov 2021)	Mr Colin Skidmore (Consultant)	AIG	Member
Tarcoola Exploration Results (after 15 Nov 2021)	Mr Marc Twining (Employee)	AusIMM	Member
Tunkillia Exploration Results (until 15 Nov 2021)	Mr Colin Skidmore (Consultant)	AIG	Member
Tunkillia Exploration Results (after 15 Nov 2021)	Mr Marc Twining (Employee)	AusIMM	Member
Tunkillia Mineral Resource	Mr Ian Taylor (Consultant)	AusIMM	Fellow
Challenger Mineral Resource (above 215mRL)	Mr Ian Taylor (Consultant)	AusIMM	Fellow
Challenger Mineral Resource (below 90mRL)	Mr Dale Sims	AusIMM / AIG	Fellow / Member
Wudinna Mineral Resource (Clarke Deposit)	Ms Justine Tracey	AusIMM	Member
Wudinna Mineral Resource (all other Deposits)	Mrs Christine Standing	AusIMM / AIG	Member / Member

The information relating to historic Exploration Results and Mineral Resources in this announcement is extracted from the Company’s Prospectus dated 14 May 2021 or as otherwise noted in this announcement, available from the Company’s website at www.bartongold.com.au or on the ASX website www.asx.com.au. The Company confirms that it is not aware of any new information or data that materially affects the Exploration Results and Mineral Resource information included in previous announcements and, in the case of estimates of Mineral Resources, that all material assumptions and technical parameters underpinning the estimates, and any production targets and forecast financial information derived from the production targets, continue to apply and have not materially changed. The Company confirms that the form and context in which the applicable Competent Persons’ findings are presented have not been materially modified from the previous announcements.

Cautionary Statement Regarding Forward-Looking Information

This document may contain forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “expect”, “target” and “intend” and statements than an event or result “may”, “will”, “should”, “would”, “could”, or “might” occur or be achieved and other similar expressions. Forward-looking information is subject to business, legal and economic risks and uncertainties and other factors that could cause actual results to differ materially from those contained in forward-looking statements. Such factors include, among other things, risks relating to property interests, the global economic climate, commodity prices, sovereign and legal risks, and environmental risks. Forward-looking statements are based upon estimates and opinions at the date the statements are made. Barton undertakes no obligation to update these forward-looking statements for events or circumstances that occur subsequent to such dates or to update or keep current any of the information contained herein. Any estimates or projections as to events that may occur in the future (including projections of revenue, expense, net income and performance) are based upon the best judgment of Barton from information available as of the date of this document. There is no guarantee that any of these estimates or projections will be achieved. Actual results will vary from the projections and such variations may be material. Nothing contained herein is, or shall be relied upon as, a promise or representation as to the past or future. Any reliance placed by the reader on this document, or on any forward-looking statement contained in or referred to in this document will be solely at the readers own risk, and readers are cautioned not to place undue reliance on forward-looking statements due to the inherent uncertainty thereof.

SOURCE: Barton Gold Holdings Limited

View the original press release on ACCESS Newswire

Bloomberg Television 6:30 PM ET as Sponsored Programming – With TV Commercials Debuting by Laser Photonics $LASE, Synergy CHC $SNYR, Sustainable Green Team $SGTM, and Acurx Pharmaceuticals $ACXP

NEW YORK CITY, NEW YORK / ACCESS Newswire / September 26, 2025 / New to The Street, a leading national business television series, announces its upcoming broadcast airing Saturday, September 27, 2025 at 6:30 PM ET on Bloomberg Television, featuring an exclusive interview with NeOnc Pharma, Inc. (NASDAQ:NTHI). The segment spotlights Amir Heshmatpour, Executive Chairman of the Board and President of NeOnc Pharma, as he shares the company’s groundbreaking work focused on advanced brain cancer treatments.

This special broadcast will also include feature segments with other disruptive and high-growth companies:

• FLOKI – a global cryptocurrency project continuing to expand its ecosystem and investor community.

• XION – an emerging technology innovator reshaping digital experiences.

• Sharps Technology, Inc. (NASDAQ:STSS) – a medical device company committed to safer, more sustainable syringe technologies.

• Aeries Technology (NASDAQ:AERT) – a provider of transformative technology solutions for enterprises worldwide.

Complementing the programming, sponsored television commercials will debut from Laser Photonics (NASDAQ:LASE), Synergy CHC (OTCQB:SNYR), Sustainable Green Team (OTCID:SGTM), and Acurx Pharmaceuticals (NASDAQ:ACXP), further amplifying the visibility of these innovative brands.

“We are committed to highlighting companies making an impact across healthcare, technology, and finance. NeOnc Pharma’s leadership in addressing brain cancer is an especially powerful story for our audience,” said Vince Caruso, Co-Founder and CEO of New to The Street.

The program continues New to The Street’s mission of delivering Predictable Media™-providing public companies with national exposure through sponsored programming on leading networks, digital platforms, and its rapidly growing YouTube channel.

About New to The Street
New to The Street is a nationally recognized television program showcasing public and private companies, their business leaders, and innovative products and services. With nationwide broadcasts on Fox Business and Bloomberg, a YouTube channel with more than 3.5 million subscribers, and strategic earned media and billboard support, New to The Street is one of the most visible and effective financial media platforms in the United States.

Media Contact:
Monica Brennan
New to The Street
Email: Monica@NewToTheStreet.com

SOURCE: New To The Street

View the original press release on ACCESS Newswire

The Expanded Program Introduces Gold and Silver Tiers, Recognizing Excellence Across All Levels of the Industry

GRANDVILLE, MICHIGAN / ACCESS Newswire / September 26, 2025 / The Haunted Attraction Association (HAA), the only official association in the haunted house industry, has certified 67 haunted attractions nationwide as 2025 Top Haunts. This year marks an expansion of the program with the introduction of Gold and Silver levels, broadening recognition to include newer and mid-size attractions that demonstrate excellence in safety, education, and operations.

The 2025 honorees include:

• 53 Iconic Haunts (Platinum) – operating 10+ years and welcoming 10,000+ annual guests

• 7 Gold Haunts – operating 5+ years with 5,000+ annual guests

• 7 Silver Haunts – operating 2+ years with 3,000+ annual guests

“Being named a Top Haunt is one of the highest honors in our industry,” said Jim Werner, President of the Haunted Attraction Association. “The new Gold and Silver categories allow us to recognize more attractions that are doing incredible work while upholding our shared values.”

“The Top Haunts program has always represented the best of the best,” added Brett Molitor, HAA Top Haunts Director. “This year’s 67 certified attractions showcase the strength and creativity of the haunted attraction industry across all sizes and markets.”

2025 HAA Top Haunts Honorees

Iconic (Platinum) Haunts

• Akron Haunted Schoolhouse and Haunted Laboratory – Akron, OH

• Boone Hall Fright Nights – Mount Pleasant, SC

• Creepy Hollow Haunted House – Rosharon, TX

• Dark Hour Haunted House – Plano, TX

• Dark Prison – Carson City, NV

• Delusion – Los Angeles, CA

• Dread Hollow – Chattanooga, TN

• Factory of Terror – Canton, OH

• Fariston’s Haunted Forest and Myrtle’s Manor – London, KY

• Fear Factory Haunted Attraction – Salt Lake City, UT

• Fear Farm – Scottsdale, AZ

• Field of Screams – Mountville, PA

• Field of Scream MT – Victor, MT

• Fright Nights at the South Florida Fairgrounds – West Palm Beach, FL

• Fright Nights WV – Daniels, WV

• Frightland – Middletown, DE

• Frightmare Farms Haunted Scream Park – Palermo, NY

• Ghostly Manor – Sandusky OH

• Halloween Nights of Eastern State Penitentiary – Philadelphia, PA

• Haunted Hollow – Rockwood, Pa

• Hobb’s Grove – Sanger, CA

• House of Torment – Austin, TX

• Haunted Hunt Club Farm – Virginia Beach, VA

• Headless Horseman Hayrides & Haunted Houses – Ulster Park, NY

• Hundred Acres Manor – Pittsburgh, PA

• Hysterium – Fort Wayne, IN

• Legends of Fear – Shelton, CT

• Los Angeles Haunted Hayride – Los Angeles, CA

• Nashville Nightmare – Nashville, TN

• Niles Scream Park – Niles, MI

• Pennhurst Asylum – Spring City, PA

• Realm of Terror – Round Lake Beach, IL

• Reapers Revenge – Blakely PA

• Scaregrounds PDX – Portland, OR

• Shocktoberfest – Reading PA

• Sinister Tombs Haunted House – Eastview, KY

• Sir Henry’s Haunted Trail – Plant City, FL

• Spook Hollow – Marquette Heights, IL

• Spooky Ranch – Columbia Station, OH

• Terror in the Corn – Erie, CO

• Terror on the Fox – Green Bay, WI

• The Castle of Chaos Haunted House – Midvale, UT

• The Dent Schoolhouse – Cincinnati, OH

• The Devils Attic – Louisville, KY

• The Haunted Farm – Hendersonville, NC

• The Queen Mary’s Dark Harbor – Long Beach, CA

• USS Nightmare – Newport, KY

• Wiard’s Orchards’ Night Terrors – Ypsilanti, MI

• Woods of Terror – Greensboro, NC

• 13th Floor Haunted House Chicago – Chicago, IL

• 13th Floor Haunted House Denver – Denver, CO

• 13th Floor Haunted House Phoenix – Phoenix, AZ

• 13th Floor Haunted House San Antonio – San Antonio, TX

Gold Haunts

• 13th Floor Haunted House Houston – Houston, TX

• 13th Floor Haunted House Jacksonville – Jacksonville, FL

• Cinema of Horrors Haunted House – Kelso, WA

• Magic of the Jack O’Lanterns Denver – Denver, CO

• New Orleans Nightmare – New Orleans, LA

• Terror Manor – Roanoke City, VA

• The Old Joliet Haunted Prison – Joliet, IL

Silver Haunts

• Aura Haunted House – Peoria, IL

• Black Water Grave – Bartow, FL

• Festival Fright Nights – San Jose, CA

• Magic of the Jack O’Lanterns LA – Los Angeles, CA

• Milltown Haunt – Lovettsville, VA

• Nightmares on the Rogue Haunted Attraction – Medford, OR

• The Haunt PA – Schaefferstown, PA

TOP HAUNTS QUALIFICATION DETAILS

To be recognized as a Top Haunt, attractions must:

• Be an active HAA member

• Operate as a commercial haunted attraction

• Carry at least $1 million in general liability insurance

• Complete the C.H.A.O.S. safety program

• Be registered and inspected by state and local authorities

• Provide an employee handbook to all staff

• Maintain a documented emergency program/plan

• Respect other attractions and professionally represent the industry

• Show a pattern of continual reinvestment in their attraction

• Demonstrate a commitment to improving the industry as a whole

• (Recommended) Conduct background checks for staff

Attractions are recognized at one of three levels based on their years of operation and annual attendance.

ABOUT THE HAUNTED ATTRACTION ASSOCIATION

The Haunted Attraction Association (HAA) is the only official association in the haunt industry, serving as the voice of haunted attraction owners, operators, designers, vendors, and enthusiasts. Through tradeshows, supplier partnerships, and educational programs, HAA champions excellence and growth in this industry. Membership is open to anyone involved in the haunted attraction industry from home haunters to large attractions. Visit www.HauntedAttractionAssociation.com.

SOURCE: Haunted Attraction Association

View the original press release on ACCESS Newswire